Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
BUSINESS
Astellas/Seattle Genetics Nabs FDA OK for 1st-in-Class ADC
Astellas Pharma and Seattle Genetics said on December 18 that they have won the US FDA’s accelerated approval for their antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) for the treatment of certain adult patients with advanced urothelial cancer. The quick green…
To read the full story
Related Article
- Astellas’ Padcev Receives Bladder Cancer Nod in Europe
April 15, 2022
- Key EU Panel Backs Padcev Again for Bladder Cancer
March 2, 2022
- Astellas’ Padcev Gets Key European Backing for Bladder Cancer
December 21, 2021
- Astellas/Seagen’s ADC Padcev Snags Full Approval, Label Expansion
July 13, 2021
- FDA Accepts Astellas/Seagen’s Submissions for Padcev’s Full Approval, Label Expansion
April 21, 2021
- EMA Accepts Regulatory Filing of Enfortumab Vedotin: Astellas/Seagen
March 29, 2021
- Astellas/Seagen Seek Padcev’s Full Approval, Label Expansion in US
February 22, 2021
- Enfortumab Vedotin Gets FDA Priority Review for Urothelial Cancer: Astellas/Seattle Genetics
September 18, 2019
BUSINESS
- Sanofi’s ITP Drug Wayrilz Goes on Sale in Japan
October 21, 2026
- Maruho Secures South Korean Rights to Incyte’s Ruxolitinib Cream
October 21, 2026
- CMIC Turns to AI to Hear Job Applicants in Their Own Words
October 21, 2026
- Arthur D. Little Urges Pricing Revamp to Spur Regenerative Medicine in Japan
October 21, 2026
- Entyvio PIV Trial Links Disease Clearance to 70% Lower UC Complication Risk
October 21, 2026
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…